Biotech Values

[biomaven0]

GIST: Gleevec is 1st line, Sutent 2nd line

Thanks.

Based on the published kinase data, seems like a no-brainer to try pona as 2nd line, and eventually 1st line. It's not something Ariad has talked about at all, so I suppose there could be some issue with the kinase assays not reflecting in vivo performance.

Here is a conclusion of a recent article:

In summary, our data indicate that ponatinib, which is currently
under investigation in phase II clinical trials for imatinib-resistant
CML, is active in vitro against CUX1-FGFR1, FIP1L1-PDGFRA-T674I,
FIP1L1-PDGFRA-D842V and against specific KIT mutants. Its
potential in the therapeutic management of EMS, primary or
secondary imatinib-resistant GIST, or imatinib-resistant FIP1L1-
PDGFRA-positive disease, needs further evaluation.

Peter